Intravesical Chemotherapy: Procedure & What to Expect

Intravesical chemotherapy is the direct delivery of a cancer-killing drug into your bladder through a thin catheter, most commonly after surgical removal of a bladder tumor. The drug bathes the inner lining of the bladder for a set period, then you urinate it out. It is the standard approach for reducing the chance that non-muscle-invasive bladder cancer comes back, and for most people the procedure itself is brief, outpatient, and tolerable, though not without discomfort and side effects worth understanding in advance.

Why the Drug Goes Directly Into the Bladder

When bladder cancer is caught early and has not grown into the muscle wall, surgeons remove visible tumors during a procedure called transurethral resection of bladder tumor (TURBT). The problem is that cancer cells can reimplant in the bladder lining even after a thorough resection. Delivering chemotherapy straight into the bladder right after surgery targets those loose cells before they can take hold. As researchers have described it, immediate post-TURBT instillation prevents tumor cell implantation facilitated by the surgical disruption, and can also eliminate small cancers or precancerous cells present in the lining at the time of surgery.¹

Because the drug stays inside the bladder rather than circulating through the bloodstream, you get a high concentration at the tumor site with far fewer whole-body side effects than intravenous chemotherapy. That local confinement is one of the biggest practical advantages: most people do not experience the nausea, hair loss, or immune suppression associated with systemic chemo.

The Drugs Used Most Often

Several chemotherapy agents can be instilled into the bladder, and your doctor’s choice depends on your cancer’s risk category, what is available, and how you have responded to earlier treatment.

Mitomycin C (MMC): The most widely studied intravesical chemotherapy drug. A meta-analysis found a roughly 37% reduction in the risk of cancer recurrence with MMC treatment.²
Gemcitabine: Increasingly popular and associated with about a 24% reduction in recurrence risk. It tends to be better tolerated than MMC and has become an important alternative during drug supply issues.²
Epirubicin: An anthracycline sometimes used as a single immediate instillation after surgery.
Thiotepa: An older agent now less commonly chosen because of a higher rate of absorption into the bloodstream and resulting blood-count drops.

The difference in recurrence reduction between MMC and gemcitabine may relate to how well each drug penetrates the bladder wall. MMC has chemical properties that favor absorption into the tissue lining, which could explain its stronger performance in pooled analyses.²

How to Prepare Before an Instillation

Preparation is less involved than you might expect, but a few steps can make the treatment work better and reduce side effects. Your clinic will give specific instructions, but common guidance includes:

Limiting your fluid intake for several hours before the appointment helps keep urine production low so the drug is not diluted inside the bladder. One study tested having patients fast from fluids for six hours before MMC instillation, and also tested using a medication called desmopressin to reduce urine output; both strategies aimed at maintaining a higher drug concentration during the dwell time.³ In practice, most clinics simply ask you to restrict fluids rather than prescribe extra medications.

For MMC specifically, some protocols add urinary alkalinization, which means taking oral sodium bicarbonate before treatment to make your urine less acidic. This stabilizes MMC in the bladder and may improve its effectiveness. In one protocol, patients in an optimized group underwent urinary alkalinization before receiving their MMC instillation.⁴

Beyond these drug-specific steps, you should tell your care team about any urinary tract infections, bleeding, or catheter-related discomfort before the procedure. Active infection or a traumatic catheterization can increase the risk of the drug being absorbed into the bloodstream rather than staying in the bladder.

What Happens During the Procedure

The instillation itself typically takes place in an outpatient clinic or a treatment room. A nurse or physician inserts a thin, flexible urinary catheter through your urethra into the bladder. The chemotherapy solution, which has been prepared under strict safety protocols, is then instilled through the catheter. The catheter is usually removed right away, leaving the drug inside. In some clinics a closed instillation system is used to minimize exposure risk for staff and patients alike.⁵

You then hold the drug in your bladder for a prescribed dwell time, usually one to two hours depending on the agent. During that period, some clinics ask you to reposition yourself periodically, rolling from side to side and onto your stomach and back, so the drug contacts the entire bladder lining. When the dwell time is up, you urinate the drug out. Nurses may instruct you to sit while urinating (to limit splashing), flush twice, and wash your hands and genital area thoroughly afterward. These precautions protect you and anyone else from contact with the chemotherapy residue.

Staff handling the drug wear gloves, gowns, and eye protection, and transport the chemotherapy in puncture-resistant containers labeled for hazardous materials.⁵ You do not need to worry about managing any of that; the clinic team takes care of safe handling. But it is worth knowing that for six to eight hours after treatment, your urine contains traces of chemotherapy. Most clinics advise flushing after each bathroom use and avoiding contact between your urine and other household members during that window.

Side Effects and How They Are Managed

Because the drug stays local, intravesical chemotherapy produces a different side-effect profile than what most people associate with chemo. The most common complaint is chemical cystitis, an irritation of the bladder lining that causes frequent urination, urgency, and a burning sensation. With MMC, the main complications are this chemical cystitis along with contact dermatitis on the hands, genitals, or any skin the drug touches. Allergic reactions can also occur.⁶ Most of these issues resolve once treatment stops, and topical steroid creams can manage skin reactions.

Thiotepa, though less commonly used today, stands out for a higher risk of blood-count changes because it can be absorbed through the bladder wall into the bloodstream. Historical data show that white blood cell drops occurred in roughly 8% to 54% of patients treated with thiotepa, and platelet drops in 3% to 31%. Irritative voiding symptoms ranged from 12% to 69%.⁶ Those wide ranges reflect differences in dose, schedule, and how studies measured side effects, but they help explain why MMC and gemcitabine have largely replaced thiotepa.

Gemcitabine is generally the gentlest on the bladder, with lower rates of irritation and dermatitis compared to MMC. When patients do experience bladder irritation from any agent, drinking plenty of fluids after the dwell period and using over-the-counter bladder-soothing medications (phenazopyridine, for example) can help. Your doctor may also delay or reduce the dose if symptoms are severe.

Intravesical Chemotherapy Versus BCG Immunotherapy

You will hear about BCG (bacillus Calmette-Guérin) in almost any conversation about bladder cancer treatment, and understanding where it fits relative to chemotherapy helps set expectations. BCG is a live but weakened bacterium originally developed as a tuberculosis vaccine. When instilled into the bladder, it triggers an immune response that attacks cancer cells. BCG is the first-line treatment for high-risk non-muscle-invasive bladder cancer and carcinoma in situ.⁷

Chemotherapy and BCG are not interchangeable. For low-risk cancers, a single dose of chemotherapy right after surgery is often all that is recommended. For intermediate-risk disease, either adjuvant chemotherapy or BCG may be used. For high-risk disease, BCG with a maintenance schedule remains the gold standard. In some intermediate- and high-risk patients, combining both approaches has shown benefit: giving MMC before scheduled BCG dosing has improved disease-free intervals.⁷

BCG comes with its own set of side effects, including flu-like symptoms, fever, and, in rare cases, a serious systemic infection called BCG sepsis. That complication is uncommon but can be life-threatening and requires immediate antituberculosis treatment rather than waiting for lab confirmation.⁸ Anti-inflammatory medications and corticosteroids can manage many of BCG’s immune-related complications.⁹

Treatment Schedules and How Long They Last

The simplest schedule is a single instillation given within the first few hours after tumor resection. For lower-grade tumors, evidence suggests this single immediate dose can be just as effective as a longer course of maintenance instillations, and it is substantially cheaper.¹⁰

When maintenance therapy is warranted, schedules vary widely. Some are as short as three months; others stretch to three years. The most common approach is monthly instillations for about a year.¹¹ Research on intermediate-risk patients suggests the sweet spot is roughly ten to eleven months of maintenance treatment, with a meaningful improvement in three-year relapse-free survival for patients who continue beyond six months.¹²

Sticking with the full schedule is harder than it sounds. In one large analysis of compliance, only about 10% of patients on the longer three-year BCG maintenance protocol completed all 21 prescribed treatments. Among those on monthly BCG or MMC maintenance for a year, roughly half finished the course.¹³ Side effects, scheduling burden, and the cumulative discomfort of repeated catheterizations all contribute to people stopping early. If you are struggling with a maintenance regimen, talking to your care team about adjusting the schedule or switching agents is far better than quietly dropping out.

When First-Line Treatment Fails

Bladder cancer that recurs despite BCG therapy is a frustrating situation, and historically the main option was radical cystectomy, the surgical removal of the entire bladder. Combination intravesical chemotherapy has emerged as an alternative for patients who are not candidates for or do not want major surgery. The most studied combination is gemcitabine plus docetaxel. A typical regimen involves six weekly instillations followed by monthly maintenance treatments for those who show no disease at their first follow-up cystoscopy.¹⁴

Results with gemcitabine/docetaxel are encouraging. In a prospective study, the one-year high-grade disease-free survival was about 67% overall, and reached 73% in patients whose cancer had specifically failed BCG.¹⁵ Longer-term data show two-year recurrence-free survival between roughly 37% and 62%, with progression-free survival of 70% to 95%, and serious adverse events in only 3% to 8% of patients.¹⁶ Those numbers make this doublet regimen a meaningful bladder-preserving option when BCG is no longer effective.

Device-Assisted Delivery

Standard instillation relies on passive contact between the drug solution and the bladder wall. Newer approaches use devices to push drugs deeper into the tissue. The two main techniques are chemohyperthermia (heating the drug solution inside the bladder) and electromotive drug administration (using a mild electrical current to drive the drug into the tissue). Both have shown improved cancer-killing effectiveness compared to standard intravesical chemotherapy, and their results have been comparable to BCG in patients with intermediate- or high-risk disease.¹⁷

A meta-analysis found that neither chemohyperthermia nor electromotive delivery showed a statistically significant difference in cancer outcomes compared to BCG, but both produced significantly lower rates of fever, which is a persistent nuisance with BCG therapy.¹⁸ These technologies are also being explored as salvage options for patients whose cancer has stopped responding to BCG.¹⁷ Availability varies by institution, and device-assisted treatments are not yet standard everywhere, but they represent a meaningful step forward in making intravesical therapy more effective without increasing side effects.

The Real-World Burden on Patients

Clinical trial endpoints like “recurrence-free survival” capture only part of what it is like to go through this treatment. Surveys of people receiving intravesical therapy in the United States paint a more candid picture. Participants reported substantial symptom burden, and among those who were employed, about half reported significant work impairment and roughly 60% reported overall work productivity loss due to their bladder cancer and its treatment.¹⁹

The repeated clinic visits, the catheterizations, the hours of holding drug in your bladder, and the urinary symptoms afterward add up over weeks and months. This cumulative toll is a major reason why compliance drops off during maintenance therapy. It is worth having an honest conversation with your doctor about what the schedule will demand and whether the expected benefit justifies the burden for your particular risk category. For some patients with low-risk disease, a single post-operative dose may be all that is needed, sparing them the grind of long-term maintenance.

The Cost Picture

Bladder cancer, per patient, ranks as one of the most expensive malignancies to treat, largely because of the ongoing surveillance and repeated treatments the disease requires.²⁰ Intravesical treatment is a significant contributor to that cost.²¹ Yet there is an irony: using a single immediate post-operative instillation of chemotherapy actually saves money compared to omitting it, because fewer recurrences mean fewer repeat surgeries and follow-up treatments down the line. One analysis estimated three-year savings of roughly $540 to $690 per patient, which would translate to tens of millions of dollars nationally if the practice were universally adopted.²²

Financial toxicity, the harmful effects that treatment costs have on your daily life, is a growing concern in bladder cancer care. Strategies under investigation to reduce it include using gemcitabine-docetaxel instead of BCG for some high-risk patients (partly a cost and supply issue), home-based BCG instillation, and optimizing surveillance schedules to reduce unnecessary follow-up visits.²⁰

The BCG Shortage and What It Means for You

If your doctor recommends intravesical chemotherapy instead of BCG, it may partly reflect a global supply problem that has simmered for over a decade. BCG is a biologic product manufactured by only a handful of companies worldwide. When one major manufacturer suspended production in 2012, the effects rippled through treatment patterns globally.²³

In the United States, BCG use dropped almost 6% during the shortage period, and the proportion of patients completing a full induction course fell from 31% to about 28%. The impact was uneven: 84% of states that reported data saw decreased BCG use, with declines ranging from 5% to 36%.²⁴ The shortage pushed clinicians and researchers to take a harder look at chemotherapy alternatives. Both MMC and gemcitabine have shown similar effectiveness to BCG in smaller studies, and the gemcitabine-docetaxel combination has gained traction as a viable substitute.²⁵

The shortage has not fully resolved. If BCG is unavailable or rationed at your treatment center, an intravesical chemotherapy regimen is not a second-rate fallback. For many patients it offers comparable cancer control with a more predictable side-effect profile. What matters most is that you receive some form of adjuvant intravesical treatment rather than none at all.